Press Releases

Biosimilars raise novel and complex questions of science and law that require updated legal and regulatory frameworks

The Biotechnology Industry Organization (BIO) applauds the United States and Chinese governments for a successful 2014 U.S.-China Joint Commission on Commerce and Trade (JCCT).


Companies to share their stories with top public and venture capital investors

The Environmental Protection Agency’s (EPA) delays in administering the Renewable Fuel Standard (RFS) generate uncertainty for the advanced biofuel industry and undercut investment, BIO said today in reaction to the House Oversight and Government Reform Subcommittee on Energy Policy, Health Care & Entitlements’ hearing on the agency’s administration of the program.

Washington, D.C. (December 9, 2014) – The Biotechnology Industry Organization (BIO) applauds today’s declaration by Health and Human Services Secretary Sylvia M. Burwell under the Public Readiness and Emergency Preparedness (PREP) Act which will help advance the development and availability of experimental Ebola vaccines. The declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of three experimental Ebola vaccines.

BIO applauds the unanimous House passage late Wednesday of the Adding Ebola to the FDA Priority Review Voucher Program Act. The Act would add Ebola to the Food and Drug Administration’s (FDA) tropical disease priority review voucher program, under which developers of a vaccine or treatment for a qualifying tropical disease receive a voucher for FDA priority review for another product of its choice.

Washington, D.C. (December 4, 2014) – Today marks the inaugural meeting of the Blue Ribbon Study Panel on Biodefense, a bipartisan panel co-chaired by former Senator Joe Lieberman and former Governor and Homeland Security Secretary Tom Ridge. Panelists former Senator Tom Daschle, former Secretary of Health and Human Services Donna Shalala, former US Homeland Security Advisor Kenneth Wainstein, and Biotechnology Industry Organization (BIO) President and CEO and former Representative Jim Greenwood. The study will be directed by Dr. Robert Kadlec, former special assistant to the President for homeland security and senior director for biological defense policy in the White House Homeland Security Council.

Executives and investors from the biofuels, specialty enzyme, renewable chemicals, algae and agriculture industries will come together at BIO’s 9th Annual Pacific Rim Summit on Industrial Biotechnology and Bioenergy on December 7-9 in San Diego  to discuss future industry growth and partnerships.  In 2013, California’s life science industry created almost $259 billion in economic activity for the state. The biorenewables sector was instrumental in generating this growth, creating high-paying jobs and attractive economic opportunities for investors.   

EPA's decision to hold the 2014 Renewable Fuel Standard (RFS) continues the atmosphere of uncertainty for the advanced biofuel industry, even while recognizing that the previously proposed methodology was flawed.

Washington, D.C. (November 18, 2014) – BIO issued the following statement in response to a study released today by the Tufts Center for the Study of Drug Development, which estimated the cost of developing a new prescription medicine that gains marketing approval at $2.558 billion (in 2013 dollars), including the cost of promising therapies that did not achieve FDA approval. These findings represent an increase of 145 percent, or 8.5 percent compound annual growth, since a previous study in 2003, in which Tufts estimated that cost at $1.044 billion (also in 2013 dollars).

BIO today named Dr. Debbie Yaver, Director, Expression Technology, Genomics and Bioinformatics at Novozymes, as the recipient of the first annual Rosalind Franklin Award for leadership in industrial biotechnology.  The Rosalind Franklin Award is a newly established annual award to honor an outstanding woman in the field of industrial biotechnology and bioprocessing.  

With some ballots still left to be counted, it appears that Oregon voters have chosen to reject Measure 92, the state’s GMO food labeling initiative. 

While final results are still coming in, it appears that voters in Maui have chosen by a narrow margin to impose a ban on farming practices that will ultimately cut jobs and jeopardize the local economy and the future of agriculture in Hawaii. The measure affects agricultural practices on the islands of Maui, Molokai and Lanai.

Colorado voters have decisively rejected Proposition 105, the food labeling initiative on the November 4th ballot. The measure, which would have created Colorado-only food labeling regulations for certain foods made with GMO ingredients, was defeated by a margin of 67 percent to 33 percent.

BayBio, the Biotechnology Industry Organization, the Pharmaceutical Research and Manufacturers of America, the Generic Pharmaceutical Association and the Consumer Healthcare Products Association have expressed opposition to a newly introduced San Francisco drug disposal ordinance, which requires pharmaceutical companies to bear the full burden of designing, funding and operating a collection program for unused medicines in the home.

During the 2014 Pacific Rim Summit Plenary Program, CEOs, CSOs and industrial biotechnology industry veterans will highlight achievements and offer insight into the quickly changing and expanding markets of renewable specialty chemical applications, biobased products, advanced biofuels and algae bioproduction.  Panelists will compare feedstock production on a global scale and discuss solutions in logistics, feedstock availability, potential for economic growth, and exploring new markets. 

BIO today issued a call to leaders from the biotechnology, chemical and agricultural industries to submit proposals and individual papers for the 2015 World Congress on Industrial Biotechnology.  The conference will be held July 19-22, 2015 at the Palais des congrès de Montréal in Montréal, Canada.  

Abengoa Bioenergy's new cellulosic biorefinery is the realization of nearly a decade of research and development and billions of dollars in investment, encouraged by the federal Renewable Fuel Standard.

The U.S. Department of Agriculture (USDA) announced October 15 several new programs aimed at addressing weeds management.  New and diverse strategies are needed for farmers to better fight weeds in today’s agricultural systems says the Biotechnology Industry Organization (BIO).

With a growing industrial biotech sector that is home to more than 400 biotechnology companies, San Diego is set to host BIO’s 2014 Pacific Rim Summit on Industrial Biotech & Bioenergy.  San Diego-based industrial biotechnology companies continue to deliver next generation products and innovative technology solutions, many of which will be highlighted during the programming at this year’s Summit.  The 2014 Pacific Rim Summit on Industrial Biotech & Bioenergy will be held December 7-9, 2014 in San Diego, California at the Westin Gaslamp Quarter.   

A new report from USDA, "Why Biobased?," provides an initial quantification of new jobs and other economic opportunities in the emerging bioeconomy. USDA also commissioned a larger, more comprehensive report that BIO hopes will be issued on a regular basis.